NCT07090486Completed
A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.
Impact of Nirmatrelvir-ritonavir on Changes in Healthcare Utilization and Frailty Following COVID-19: a Difference-in-difference Analysis
Source: ClinicalTrials.gov · Last updated 29 Jul 2025
Brief summary (registry, in English)
This is a cohort study that will include Paxlovid (nirmatrelvir-ritonavir) treatment eligible for people with a positive SARS-CoV-2 diagnostic test and at least one COVID-19 symptom. This study will look at the change in Post Covid Conditions measured by the number of outpatients, Emergency department, urgent care and inpatient visits before and after COVID-19 between those who did and did not receive Paxlovid. In addition, changes in frailty post-acute infection will be evaluated, in a separate analysis. It is hypothesized that individuals with COVID-19 who received Paxlovid will have a smaller post-COVID-19 increase (vs pre-COVID) in PCC healthcare utilization (i.e., cardiopulmonary) in comparison to patients with COVID-19 who did not receive Paxlovid.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 14000 (actual)
- First submitted
- 21 Jul 2025
- Start date
- 15 Apr 2025
- Primary completion date
- 15 Apr 2025
- Lead sponsor
- Pfizer
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT07090486
What you commit to
- Study type: Observational
- Participants enrolled: 14000
- From 15 Apr 2025 to the primary completion date, 15 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals on another medication that is contraindicated for treatment with nirmatrelvir-ritonavir defined as having any prescription drug claim in the 90 days prior to COVID-19 symptom onset
- Receipt of any COVID-19 antiviral (molnupiravir, remdesivir, nirmatrelvir/ritonavir) or monoclonal antibody treatment (bamlanivimab, bebtelovimab, casirivimab/imdevimab, cilgavimab/tixagevimab, otrovimab,) \<180 days prior to COVID-19 symptom onset
- Any positive SARS-CoV-2 test, including self-reported tests, \<180 days prior to COVID-19 symptom onset.
Who the study is looking for
- Developed at least one COVID-19 symptom between Apr 1, 2022 through Dec 31, 2023
- A positive lab-confirmed polymerase chain reaction (PCR) SARS-COV-2 test 5 days after symptom onset (primary analysis).
- Continuous enrollment in KPSC health plans for at least 1 year (allowing for a 31-day gap to account for potential delays in membership renewal) before the date of symptom onset
- Active membership in KPSC health plans for at least 31 days after the date of symptom onset
- Eligible for nirmatrelvir-ritonavir defined by age and CDC-defined risk factors for severe COVID-19
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer New York Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.